Skip to content
This content is selected and controlled by WebMD's editorial staff and is brought to you by EMD Serono, Inc. and Pfizer Inc.

How Well Are You Managing MS?

Answer a few questions, and you'll get:

  • Treatment options for your type of MS
  • Information about the progression of the disease
  • Tips for dealing with symptoms while still enjoying life

Reviewed by Neil Lava, MD on April 14, 2014

Sources:

National MS Society.

Multiple Sclerosis International Federation. “World of MS - Resources - Clinically isolated syndrome.”

McDonald, W. I, A. Compston, G. Edan, D. Goodkin, H. P Hartung, F. D Lublin, H. F McFarland, D. W Paty, C. H Polman, and S. C Reingold. “Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.” Annals of neurology 50, no. 1 (2001): 121-127.

Gold, R., J. S Wolinsky, M. P Amato, and G. Comi. “Evolving expectations around early management of multiple sclerosis.” Therapeutic Advances in Neurological Disorders 3, no. 6 (2010): 351.

National Institute of Neurological Disorders and Stroke (NINDS). “Multiple Sclerosis: Hope Through Research”

Kachuck, N., and M. K Racke. “Monitoring Disease Progression: Incorporating MRI and New Modalities in Clinical Decision Making” (n.d.).

Kalb, P. D.R.C. Multiple sclerosis: The questions you have, the answers you need. Demos Health, 2008.

Crayton, H., R. A Heyman, and H. S Rossman. “A multimodal approach to managing the symptoms of multiple sclerosis.” Neurology 63, no. Issue 11, Supplement 5 (2004): S12.

Rae-Grant, A. D, N. J Eckert, S. Bartz, and J. F Reed. “Sensory symptoms of multiple sclerosis: a hidden reservoir of morbidity.” Multiple Sclerosis 5, no. 3 (1999): 179.

National MS Society. “Expert Opinion Paper: Management of MS Related Fatigue.”

Dean, L. “Comparing Drugs for Multiple Sclerosis - PubMed Health.” PubMed Health, February 11, 2011.

NAAC National Anemia Action Council. “Anemia FAQs of Symptoms, Causes, Diagnosis and Treatment.”

FDA. “U S Food and Drug Administration Home Page”

National Library of Medicine (NLM) at the National Institutes of Health (NIH). “PubMed Health”

Havrdova, E., R. Zivadinov, J. Krasensky, M. G. Dwyer, I. Novakova, O. Dolezal, V. Ticha, L. Dusek, E. Houzvickova, and J. L. Cox. “Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.” Multiple Sclerosis 15, no. 8 (2009): 965.

National Institutes of Medicine. “MedlinePlus: Drugs, Herbs and Supplements.”

Frohman, E. M, K. Brannon, M. K Racke, and K. Hawker. “Mycophenolate mofetil in multiple sclerosis.” Clinical neuropharmacology 27, no. 2 (2004): 80.

Cleveland Clinic. “Mycophenolate Mofetil (CellCept)”, n.d.

Goodin, D. S., B. G. Arnason, P. K. Coyle, E. M. Frohman, and D. W. Paty. “The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis.” Neurology 61, no. 10 (2003): 1332.

Marrie, R. A., R. Rudick, R. Horwitz, G. Cutter, T. Tyry, D. Campagnolo, and T. Vollmer. “Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis.” Neurology 74, no. 13 (2010): 1041.

Hasson, J. “Is there an MS diet?” Momentum, National MS Society, Fall 2008.

Nowack, D. “Is there a diet that helps people with MS?” Momentum, National MS Society, Fall 2008.

Schwarz, S., and H. Leweling. “Multiple sclerosis and nutrition.” Multiple sclerosis 11, no. 1 (2005): 24.

Bowling, A. “So, what’s new about Vitamin D?” InsideMS, November 2006.

Munger, K. “Vitamin D intake and incidence of multiple sclerosis.” Neurology 62 (January 13, 2004): 60-5.

Brown, T. “Exercise and rehabilitation for individuals with m... [Phys Med Rehabil Clin N Am. 2005] - PubMed result.” Physical medicine and rehabilitation clinics of North America 16 (May 2005): 513-55.

National Center of Physical Activity and Disability. “Disability/Condition: Multiple Sclerosis: Designing an Exercise Program.”

Solaro C, et al. The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. Neurology. 2004;63(5):919.

Moulin DE, Foley KM, Ebers GC. Pain syndromes in multiple sclerosis. Neurology. 1988;38(12):1830-4.

Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 2005;4(5):281.

Beck RW, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992;326(9):581.

The Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol. 1990;27(6):591.

Rudge P, et al. Randomised double blind controlled trial of cyclosporin in multiple sclerosis. JNeurol Neurosurg Psychiatry. 1989;52(5):559.

Symister, Petra; Friend, Ronald. Health Psychology. 2003.  Vol 22(2), 123-129.

Affleck, Glenn; Tennen, Howard; Apter, Andrea Chang, Edward C. Optimism & pessimism: Implications for theory, research, and practice. Washington, DC, US 2001. pp. 147-168.

Koch M, Uyttenboogaart M, Polman S, De Keyser J. Seizures in multiple sclerosis. Epilepsia. 2008;49(6):948.

Attarian HP, Brown KM, Duntley SP, Carter JD, Cross AH. The relationship of sleep disturbances and fatigue in multiple sclerosis.Arch Neurol. 2004;61(4):525.

Office of Dietary Supplements: “Dietary Supplement Fact Sheet: Vitamin D.”

Pierrot-Deseilligny, C. Clinical implications of a possible role of vitamin D in multiple sclerosis J Neurol (2009) 256:1468–1479.

National MS Society: “Exercise as Part of Everyday Life.”

National MS Society: “Exercise.”

National MS Society: “Stress.”

David C Mohr, Stacey L Hart, Laura Julian, Darcy Cox, Daniel Pelletier. Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. BMJ, 2004.

National MS Society: “Pregnancy and Reproductive Issues.”

National MS Society: “Optic Neuritis.”

National MS Society: “Clinically isolated syndrome (CIS).”

National MS Society: “Adherence. Starting a Disease-Modifying Therapy and Sticking with It.”

National MS Society: “Talking about Initiating and Adhering to Treatment with Injectable Disease-Modifying Agents.”

National MS Society: “The MS Disease-Modifying Medications.”

National MS Society: “Emotional Changes.”

Gray O, McDonnell GV, Forbes RB. Methotrexate for multiple sclerosis. Cochrane Database Syst Rev. 2004;(2):CD003208.

Goodkin  DE, Rudick  RA, VanderBrug Medendorp  S, Daughtry  MM, Schwetz  KM, Fischer  J, et al.  Low dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.  Ann Neurol.  1995;37:30–40.

Calabresi  PA, Wilterdink  JL, Rogg  JM, Mills  P, Webb  A, Whartenby  KA.  An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS.  Neurology.  2002;58:314–7.

Cohen et al. Results of the AvonexCombination Trial (ACT) in relapsing-remitting MS. Neurology 2009 Feb 10;72(6):535-41.

This tool does not provide medical advice. See additional information:

THIS TOOL DOES NOT PROVIDE MEDICAL ADVICE.  It is intended for informational purposes only. It is not a substitute for professional medical advice, diagnosis or treatment. Never ignore professional medical advice in seeking treatment because of something you have read on the WebMD Site. If you think you may have a medical emergency, immediately call your doctor or dial 911.

© 2014 WebMD, LLC. All rights reserved.

Previous Slide Next Slide
close

From Our Sponsor

Content under this heading is from or created on behalf of the named sponsor. This content is not subject to the WebMD Editorial Policy and is not reviewed by the WebMD Editorial department for accuracy, objectivity or balance.

Rebif is used to treat relapsing forms of MS to decrease the frequency of relapses and delay the occurrence of some of the physical disability that is common in people with MS. Rebif is not approved for treatment of chronic progressive MS.

Important Safety Information

Before beginning treatment, you should discuss the potential benefits and risks associated with Rebif with your healthcare provider.

Rebif can cause serious side effects. Tell your healthcare provider right away if you have any of the symptoms listed below while taking Rebif.

  • Behavioral health problems, including depression and suicidal thoughts. You may have mood problems including depression (feeling hopeless or feeling bad about yourself), and thoughts of hurting yourself or suicide
  • Liver problems or worsening of liver problems, including liver failure. Symptoms may include nausea, loss of appetite, tiredness, dark colored urine and pale stools, yellowing of your skin or the white part of your eye, bleeding more easily than normal, confusion, and sleepiness. During your treatment with Rebif you will need to see your healthcare provider regularly and have regular blood tests to check for side effects
  • Serious allergic and skin reactions. Symptoms may include itching, swelling of your face, eyes, lips, tongue or throat, trouble breathing, anxiousness, feeling faint, skin rash, hives, sores in your mouth, or skin blisters and peels
  • Injection site problems. Symptoms at the injection site may include redness, pain, swelling, color changes (blue or black), and drainage of fluid
  • Blood problems. Rebif can affect your bone marrow and cause low red and white blood cell and platelet counts. In some people, these blood cell counts may fall to dangerously low levels. If your blood cell counts become very low, you can get infections and problems with bleeding and bruising. Your healthcare provider may ask you to have regular blood tests to check for blood problems
  • Seizures. Some people have had seizures while taking Rebif

Rebif will not cure your MS but may decrease the number of flare-ups of the disease and slow the occurrence of some of the physical disability that is common in people with MS.

Do not take Rebif if you are allergic to interferon beta, human albumin, or any of the ingredients in Rebif.

Before you take Rebif, tell your healthcare provider if you have or have had any of the following conditions:

  • mental illness, including depression, and suicidal behavior
  • liver problems, bleeding problems or blood clots, low blood cell counts, seizures (epilepsy), or thyroid problems
  • you drink alcohol
  • you are pregnant or plan to become pregnant. It is not known if Rebif will harm your unborn baby. Tell your healthcare provider if you become pregnant during your treatment with Rebif
  • you are breastfeeding or plan to breastfeed. It is not known if Rebif passes into your breast milk. You and your healthcare provider should decide if you will use Rebif or breastfeed. You should not do both

Tell your healthcare provider about all medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.

The most common side effects of Rebif include:

  • flu-like symptoms. You may have flu-like symptoms when you first start taking Rebif. You may be able to manage these flu-like symptoms by taking over-the-counter pain and fever reducers. For many people, these symptoms lessen or go away over time. Symptoms may include muscle aches, fever, tiredness, and chills
  • stomach pain
  • change in liver blood tests

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of Rebif. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call
1-800-FDA-1088.

This information is not intended to replace discussions with your doctor. For additional information about Rebif, please consult the Prescribing Information and Medication Guide and talk to your doctor. You can also visit www.rebif.com or call, toll-free, 1-877-447-3243. Rebif is available by prescription only.

Rebif, Rebif Rebidose, Rebiject II®, MS LifeLines, and the Rebif logo are registered trademarks of EMD Serono, Inc. or its affiliates.

Brought to you by EMD Serono, Inc. and Pfizer Inc, the co-marketers of Rebif in the US.

Full Prescribing Information (PDF) | Medication Guide (PDF)

This information is intended only for residents of the United States.

US-INF-0414-0058a RBU659300